Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,839 shares of the biopharmaceutical company’s stock after selling 21,431 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Regeneron Pharmaceuticals were worth $41,872,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. West Paces Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. Sachetta LLC increased its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on REGN shares. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Truist Financial reissued a “buy” rating and issued a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Royal Bank of Canada reissued an “outperform” rating and issued a $1,250.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, September 5th. Finally, StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,109.70.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The disclosure for this sale can be found here. Insiders have sold 11,561 shares of company stock worth $13,095,105 over the last three months. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 0.4 %

REGN opened at $1,141.45 on Thursday. The business’s fifty day moving average is $1,119.03 and its two-hundred day moving average is $1,023.84. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a market cap of $125.77 billion, a price-to-earnings ratio of 33.72, a PEG ratio of 3.86 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the business earned $8.79 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.